NCT06524518Not yet recruitingPhase 2
Xuanwu Hospital Capital Medical University
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Not yet recruiting
- Sponsor
- Xuanwu Hospital, Beijing
- Enrollment
- 213
- Locations
- 1
- Primary Endpoint
- DFS
Study Overview
Brief Summary
A prospective, multicenter clinical study designed to explore the efficacy of adaptive therapy based on MRD status in patients with stage II-III non-small cell lung cancer(NSCLC) after treatment. Primary endpoints include 3-year Disease-Free Survival rate (3y-DFS) and median disease-free survival (mDFS).
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Prevention
- Masking
- Single (Investigator)
Eligibility Criteria
- Ages
- 18 Years to 80 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Age: 18-80 years old
- •gender: men and women can be balanced as far as possible
- •Patients with clinically confirmed stage II-III NSCLC by histopathology have operable conditions
- •no previous exposure to immune-mediated therapy, including but not limited to other anti-CTLA-4, anti-PD-1, anti-PD-L1 And anti-PD-L2 antibodies
- •ECOG behavior status score 0 ~ 1
- •EGFR or ALK driver gene mutation negative
- •organ function level meets the conditions: 1) Hematological examination indicators: absolute neutrophil count (ANC) ≥1.8×109/L, platelet count ≥ 100×109/L, hemoglobin ≥9 g/dL.
- •Appropriate liver function: total bilirubin ≤ 1.5× upper limit of normal (ULN), aspartate aminotransferase (AST), Alanine aminotransferase (ALT) ≤2.5×ULN 3) Appropriate renal function: serum creatinine ≤1.25×ULN, or creatinine clearance ≥60 mL/min
- •Sign informed consent
Exclusion Criteria
- •Any other anti-tumor treatment before surgery
- •Patients with previous history of other malignant tumors
- •Have a history of interstitial lung disease, drug-induced interstitial disease or any active interstitial lung disease with clinical evidence
- •CT scan at baseline revealed idiopathic pulmonary fibrosis.
- •Pregnant or lactating women
- •multiple lung cancer patients
- •Patient's organ system status:
- •Prior interstitial lung disease, drug-induced interstitial disease, radiation pneumonia or REN requiring hormone therapy Any clinical evidence of active interstitial lung disease 2) In the investigator's judgment, there is a severe or uncontrollable systemic disease (e.g. unstable or uncompensable) Evidence of respiratory, heart, liver or kidney disease) 3) Any unstable systemic disease (including active infection, grade III hypertension, unstable angina, Congestive heart failure, liver, kidney or metabolic disease) 4) Can not accept oral administration, need intravenous high energy nutrition, prior surgery affecting absorption or live Patients with dynamic peptic ulcer
- •Functional level of patients with various organ lesions:
- •Bone marrow: absolute neutrophil count (ANC) < 1.5×109/L, platelets < 90×109/L or blood V1.1 2024.5.29 Albumin < 9 g/dl
- •Liver: serum bilirubin > 1.5 times the upper limit of normal
- •Serum creatinine > 1.25 times the normal value
- •any other disease, neurological or metabolic disorder, the evidence of physical examination or laboratory test results is reasonable Suspected illness or presence of counterindications of use of related drugs or placing subjects at high levels of treatment-related complications The possibility of risk.
- •No R0 resection [ananatomical lobectomy/total pulmonary resection + systemic lymph node dissection (including at least 3 groups of N1) And 3 groups of N2 lymph nodes), both gross and microscopic incisal margins were negative].
- •Situations considered unsuitable for inclusion by other researchers
Arms & Interventions
MRD-negative follow-up
Sham Comparator
Intervention: Chemotherapy combined with immunization (Drug)
MRD-positive adaptive therapy
Experimental
Intervention: Chemotherapy combined with immunization (Drug)
Outcomes
Primary Outcomes
DFS
Time Frame: MRD-positive patients were treated 3 years after intervention
3 years
Secondary Outcomes
No secondary outcomes reported
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Recruiting
Phase 2
Adaptive Treatment for Acute Myeloid Leukemia Based on D14 MRD ResultsMRDAMLNCT05736978Shanghai Tong Ren Hospital58
Active, not recruiting
Not Applicable
Longitudinal Multimodal Response Assessment During Neoadjuvant Treatment of Rectal CancerLocally Advanced Rectal CarcinomaNeoadjuvant TreatmentRadiotherapyAdaptive TreatmentNCT05524012Jena University Hospital40
Completed
Phase 2
An Adaptive Algorithm-Based Approach to Treatment for Adolescent DepressionDepressive DisorderNCT03222570University of Minnesota90
Unknown
Phase 1
Multiple Treatments for Ebola Virus Disease (EVD)Ebola Virus DiseaseNCT02380625Clinical Research Management, Inc.150
Active, not recruiting
Phase 3
Australasian COVID-19 Trial (ASCOT) ADAptive Platform TrialSARS-CoV-2 Infection (COVID-19)NCT04483960University of Melbourne2,200